stockrowArrowhead Pharmaceuticals, Inc.
ARWR Healthcare Biotechnology
Arrowhead Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $829.4 million, up 23,258.2% from fiscal 2024.
- Revenue
- +171.0%
- EPS
- −7.94%
- Free cash flow
- −15.4%
- Total debt
- +259.5%
Quarter to June 2026, against a year earlier
Follow ARWR
Alert me
Arrowhead Pharmaceuticals, Inc. (ARWR) Return on assets
Arrowhead Pharmaceuticals, Inc.'s return on assets over the twelve months to 30 June 2026 was −18.3%, down 18.2 percentage points from fiscal 2025 (−0.13%). Over the past ten years it has ranged from −62.9% (fiscal 2024) to 29.5% (fiscal 2019); the current reading is higher than 91% of that period. That is above the Biotechnology industry median of −45.6% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −0.13% | 62.80 |
| FY2024 | −62.9% | (34.76) |
| FY2023 | −28.2% | (3.06) |
| FY2022 | −25.1% | (2.26) |
| FY2021 | −22.9% | (3.46) |
| FY2020 | −19.4% | (48.85) |
| FY2019 | 29.5% | 79.96 |
| FY2018 | −50.5% | (20.89) |
| FY2017 | −29.6% | 33.15 |
| FY2016 | −62.8% | (4.40) |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| CORT Corcept Therapeutics Incorporated compare | 17.2% |
| KRYS Krystal Biotech, Inc. compare | 15.9% |
| PTGX Protagonist Therapeutics, Inc. compare | 10.3% |
| CAI Caris Life Sciences,�Inc. compare | 8.58% |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −11.1% |
| ARWR Arrowhead Pharmaceuticals, Inc. | −18.3% |
| TWST Twist Bioscience Corporation compare | −20.8% |
| SYRE Spyre Therapeutics, Inc. compare | −30.9% |
| CYTK Cytokinetics, Incorporated compare | −47.7% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on ARWR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement